Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
intoplicine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| intoplicine | DRUG | - |
DISEASE CHARACTERISTICS: Histologically or cytologically proven solid tumor refractory to conventional cytotoxic anticancer therapy or for which no curative therapy exists Measurable or evaluable disease No active, progressive brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance s...
Intoplicine is an investigational small molecule being studied for the treatment of unspecified adult solid tumors, protocol specific. It is in Phase 1 clinical development for oncology indications. The drug is not approved and remains under investigation for its safety and efficacy in patients with advanced or metastatic solid tumors.
Intoplicine is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker SNY. Sanofi is conducting clinical research on this investigational oncology drug, which is currently in Phase 1 development for the treatment of solid tumors.
Intoplicine is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in early-stage clinical trials to evaluate its safety, tolerability, and potential efficacy in patients with advanced or metastatic solid tumors.
Intoplicine has been studied in one clinical trial with the identifier NCT00003713, titled 'Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors.' This Phase 1 trial enrolled 35 participants and has been completed. The study was conducted in the United States and Canada, enrolling adults aged 18 years and older.
No alternative names for intoplicine have been reported. The drug is known by its generic name intoplicine and is being developed by Sanofi. It is a distinct investigational small molecule in Phase 1 clinical trials for the treatment of solid tumors.